secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-10-20T11:00:28+00:00
Accession:  0001437749-26-032969
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Moleculin Biotech sets 1-for-20 reverse split effective Oct 20, 2026; shares outstanding fall to ~1.05M
--------------------------------------------------------------------------------

- Board approved 1-for-20 reverse split after stockholders authorized a ratio of 1-for-2 to 1-for-20 at the Oct 9, 2026 annual meeting.
- Split effective 12:01 a.m. ET Oct 20, 2026; MBRX trades post-split on Nasdaq Capital Market with new CUSIP 60855D507.
- Outstanding shares drop from ~20.91 million to ~1.05 million; authorized shares stay at 500 million; par value unchanged at $0.001.
- No fractional shares issued — holders receive cash equal to the fraction times the 5-day average closing price before the split.
- Restated post-split FY2025 net loss per share $(568.38) vs pre-split $(28.42); net loss $33.56M in FY2025 vs $26.05M in FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969/0001437749-26-032969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969/mbrx20261015d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer